PPT-Brentuximab Vedotin.
Author : luanne-stotts | Published Date : 2016-11-16
How and When Should it be Used in B and T cell Lymphomas Ranjana Advani MD Professor of Medicine Saul Rosenberg Professor of Lymphoma Stanford University Lymphoma
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Brentuximab Vedotin." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Brentuximab Vedotin.: Transcript
How and When Should it be Used in B and T cell Lymphomas Ranjana Advani MD Professor of Medicine Saul Rosenberg Professor of Lymphoma Stanford University Lymphoma and Myeloma 2014 International Congress on Hematologic Malignancies . Hodgkin Lymphoma. Program Objectives. Brentuximab Vedotin in Hodgkin Lymphoma. Brentuximab Vedotin in Patients With R/R HL. Brentuximab Vedotin: Adverse Events . Nivolumab in Relapsed/Refractory HL. Pembrolizumab in Relapsed/Refractory HL. . Vedotin. Should be the Second Line Regimen of Choice for Recurrent Hodgkin Lymphoma Prior to Stem Cell Transplant. Catherine Diefenbach, MD. Assistant Professor of Medicine. NYU . Perlmutter. Cancer Center, NYU . in CR with . Brentuximab. :. Koen van Besien, MD, PhD. Weill Cornell Medical College. Recurrent HL after . Autotransplant. in CR with . Brentuximab. :. ALLO. Koen van Besien, MD, PhD. Weill Cornell Medical College. T. ransplant . in CR on . B. rentuximab. . V. edotin. : . Allo. . Transplant . or . Maintenance . T. herapy. ?. Anas Younes, M.D.. Memorial Sloan Kettering Cancer Center. Overall Survival. <1990 median 1.9 yrs. San Francisco. , USA. Assoc. . Prof. . Shilpa Gupta. Cleveland Clinic, Ohio, USA. UROTHELIAL CANCER UPDATE. Please note: The views expressed within this presentation are the personal opinions of the author. They do not necessarily represent the views of the author’s academic institution or the rest of the GU CONNECT group.. Supported by educational grants from AbbVie, AstraZeneca, Gilead Sciences Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, and . Seattle Genetics.. CCO Independent Conference Highlights*.
Download Document
Here is the link to download the presentation.
"Brentuximab Vedotin."The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents
